Early detection of lung cancer by using an autoantibody panel in Chinese population
Shengxiang Ren(Tongji University), Fred R. Hirsch(University of Colorado Denver), Xuejun Hu(First Hospital of China Medical University), Yayi He(Tongji University), Jun Zhang(Wuhan University), Yan Li(University of Michigan), Xiaohong Xu(Zhejiang Cancer Hospital), Tao Jiang(Tongji University), Shucai Zhang(Capital Medical University), Jing Zhou(Hangzhou Cancer Hospital), Hourong Cai(Boehringer Ingelheim (United States)), Weijing Cai(Icahn School of Medicine at Mount Sinai), Xiaopeng Liu(Hangzhou Cancer Hospital), Hui Yu(University of Colorado Denver), Zhiyong Ma(Zhengzhou University), Caicun Zhou(Tongji University)
Cited by 203
Related Papers
International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma
|Journal of Thoracic Oncology|2011|4.8k
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
|The Lancet Oncology|2011|4.1k
Lung cancer: current therapies and new targeted treatments
|The Lancet|2016|3.3k
PD-L1 as a biomarker of response to immune-checkpoint inhibitors
|Nature Reviews Clinical Oncology|2021|1.5k